Andrew Combs

Insider Reports History

Location
Wilmington, DE
Signature
/s/ Krishna Vaddi, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Andrew Combs:

Company Role Class Num Shares Value Price $ Report Date Ownership
Prelude Therapeutics Inc Chief Chemistry Officer Common Stock 480,123 $332,485 $0.6925 25 Mar 2025 Direct
Prelude Therapeutics Inc Chief Chemistry Officer Employee Stock Option (right to buy) 175,000 04 Feb 2025 Direct

Insider Reports Filed by Andrew Combs

Symbol Company Period Transactions Value $ Form Type Role Filing Time
PRLD Prelude Therapeutics Inc 25 Mar 2025 1 +$69,250 4 Chief Chemistry Officer 27 Mar 2025, 16:40
PRLD Prelude Therapeutics Inc 04 Feb 2025 1 $0 4 Chief Chemistry Officer 05 Feb 2025, 16:32
PRLD Prelude Therapeutics Inc 20 Dec 2024 2 +$85,538 4 Chief Chemistry Officer 26 Dec 2024, 07:49
PRLD Prelude Therapeutics Inc 01 Mar 2024 1 $0 4 Chief Chemistry Officer 04 Mar 2024, 18:05
PRLD Prelude Therapeutics Inc 07 Feb 2023 1 $0 4 EVP, Head of Chemistry 09 Feb 2023, 15:08
PRLD Prelude Therapeutics Inc 31 Mar 2022 2 +$68,157 4 EVP, Head of Chemistry 04 Apr 2022, 17:08
PRLD Prelude Therapeutics Inc 15 Feb 2022 1 $0 4 EVP, Head of Chemistry 17 Feb 2022, 18:07
PRLD Prelude Therapeutics Inc 13 Dec 2021 2 +$94,880 4 EVP, Head of Chemistry 15 Dec 2021, 16:21
PRLD Prelude Therapeutics Inc 20 Jul 2021 1 $0 4 EVP, Head of Chemistry 22 Jul 2021, 18:07